Immunocytochemical detection of epithelial cells in the bone marrow of primary breast cancer patients: a meta-analysis

Weinschenker, Patrícia; Soares, Heloisa P.; Clark, Otávio; Giglio, Auro del

doi:10.1007/s10549-004-8691-1

Cited by 19 publications

(12 citation statements)

References 26 publications

(38 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These results are in agreement with the studies of Braun and Schindlbeck, where established pathological parameters did not predict the presence of ICC-detected CK þ in BM samples Schindlbeck et al, 2004). However, in the meta-analysis of Weinschenker, a direct correlation was observed between ICC BM positivity and the primary tumour's presence with expression of ER, large size and higher histologic grade (Weinschenker et al, 2004). In the study of Pierga et al, the presence of ICC CK þ cells in blood in patients with operable disease was correlated with negative ER and nodal involvement.…”

Section: Discussionsupporting

confidence: 91%

“…In these studies, the BM status is considered as a mirror for the efficacy of the metastatic process throughout the body, similar to detection of cancer cells in lymph nodes. Also, the prognostic relevance of DECs in BM is clearly demonstrated by a number of large studies Weinschenker et al, 2004). The vast majority of these studies used immunocytochemistry for cell detection.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Real-time RT–PCR detection of disseminated tumour cells in bone marrow has superior prognostic significance in comparison with circulating tumour cells in patients with breast cancer

et al. 2006

View full text Add to dashboard Cite

This study assessed the ability of real-time reverse transcription -polymerase chain reaction (RT -PCR) analysis to detect disseminated epithelial cells (DEC) in peripheral blood (PB) and bone marrow (BM) of patients with breast cancer (BC). Detection of DEC in BM is an obvious choice in BC, but blood sampling is more convenient. The aim of this study was to evaluate whether the detection of DEC in either PB or BM predicts overall survival (OS). Peripheral blood and BM samples were collected from 148 patients with primary (stage M0, n ¼ 116/78%) and metastatic (stage M þ , n ¼ 32/21%) BC before the initiation of any local or systemic treatment. Peripheral blood of healthy volunteers and BM of patients with a nonmalignant breast lesion or a haematological malignancy served as the control group. Disseminated epithelial cells was detected by measuring relative gene expression (RGE) for cytokeratin-19 (CK-19) and mammaglobin (MAM), using a quantitative RT -PCR detection method. The mean follow-up time was 786 days ( þ /À 487). Kaplan -Meier analysis was used for predicting OS. By taking the 95 percentile of the RGE of CK-19 (BM: 26.3 and PB: 58.7) of the control group as cutoff, elevated CK-19 expression was detected in 42 (28%) BM samples and in 22 (15%) PB samples. Mammaglobin expression was elevated in 20% (both PB and BM) of the patients with BC. There was a 68% (CK-19) and 75% (MAM) concordance between PB and BM samples when classifying the results as either positive or negative. Patients with an elevated CK-19 or MAM expression in the BM had a worse prognosis than patients without elevated expression levels (OS: log-rank test, P ¼ 0.0045 (CK-19) and P ¼ 0.025 (MAM)). For PB survival analysis, no statistical significant difference was observed between patients with or without elevated CK-19 or MAM expression (OS: log-rank test, P ¼ 0.551 (CK-19) and P ¼ 0.329 (MAM)). Separate analyses of the M0 and M þ patients revealed a marked difference in OS according to the BM CK-19 or MAM status in the M þ patient group, but in the M0 group, only MAM expression was a prognostic marker for OS. Disseminated epithelial cells, measured as elevated CK-19 or MAM mRNA expression, could be detected in both PB and BM of patients with BC. Only the presence of DEC in BM was highly predictive for OS. The occurrence of DEC in the BM is probably less time-dependent and may act as a filter for circulating BC cells. The use of either larger volumes of PB or performing an enrichment step for circulating tumour in blood cells might improve these results.

show abstract

Section: Discussionsupporting

confidence: 91%

mentioning

confidence: 99%

Real-time RT–PCR detection of disseminated tumour cells in bone marrow has superior prognostic significance in comparison with circulating tumour cells in patients with breast cancer

et al. 2006

View full text Add to dashboard Cite

show abstract

“…Numerous studies have concluded that the presence of DTC in BM, evaluated by ICC or RT-PCR, correlates strongly with an early relapse of breast cancer and decreased patient survival (Landys et al 1998, Mansi et al 1999, Braun et al 2000b, Gebauer et al 2001, Gerber et al 2001, Wiedswang et al 2003, Schindlbeck et al 2004, Weinschenker et al 2004, Pantel & Woelfle 2005, Benoy et al 2006. As demonstrated by clinical follow-up data on more than 4000 breast cancer patients studied in prospective trials by several international groups, the presence of DTC in BM (identified by ICC at primary diagnosis) predicts the postoperative occurrence of overt metastases in bone and other organs (Braun et al 2005).…”

Section: Prognosis and Correlationsmentioning

confidence: 99%

Significance, detection and markers of disseminated breast cancer cells

Lacroix¹

2006

Endocr Relat Cancer

258

220

View full text Add to dashboard Cite

The development of distant metastases is the major cause of death from breast cancer. In order to predict and prevent tumour spreading, many attempts are being made to detect small numbers of tumour cells that have shed from the primary lesions and have moved to lymph nodes, blood or bone marrow. This article presents the advantages and the limitations of techniques used for disseminated tumour cells (DTC) detection. DTC markers are listed and the most currently used of them (KRT19, CEACAM5, TACSTD1, MUC1, EGFR, ERBB2, SCGB2A2, SCGB2A1, SCGB1D2, PIP, SBEM, TFF1, TFF3, ANKRD30A, SPDEF, ESR1, SERPINB5 and GABRP) are discussed, notably on the basis of recent data on breast tumour portraits (luminal epithelial-like, basal/myoepithelial-like and ERBB2). The significance of DTC for the prognosis and prediction of response to therapy is examined. DTC viability, the notion of cell dormancy and the concept of breast cancer stem cells are also discussed.

show abstract

“…В ходе ис-следований были объединены неспецифические эпителиальные маркеры и специфические маркеры РМЖ. Установлено, что мультимаркерный подход при ПЦР-диагностике является наиболее эффектив-ным для выявления микрометастазов РМЖ в КМ [10][11][12][13][14][15][16].…”

Section: актуальная темаunclassified

Treatment of patients with bone marrow metastases: the present state of the problem

Козловская¹,

Antonenkova²,

Zhavrid³

2016

Tumors of female reproductive system

View full text Add to dashboard Cite

12М а м м о л о г и я / M a m m o l o g y 1 ' 2 0 1 6 Том 12 / Vol. 12 88.7 and 69.3 %, respectively (p < 0.01). ОПУХОЛИ ЖЕНСКОЙ РЕПРОДУКТИВНОЙ СИСТЕМЫ TUMORS OF FEMALE REPRODUCTIVE SYSTEM Key words: breast cancer, micrometastases, tumor cells in bone marrow, polymerase chain reactionРак молочной железы (РМЖ) представляет собой патогенетически полиморфное заболевание, поэтому все пациентки не могут получать одинаковое лечение с одинаковым эффектом. Несмотря на достигнутые результаты в ранней диагностике и успехи в комплекс-ной терапии (хирургическое лечение, послеопераци-онная лучевая и химиотерапия (ХТ)), безрецидивная выживаемость ограничена из-за возникновения отда-ленных метастазов, которые являются основной при-чиной смерти этой категории пациенток.По данным канцер-регистра Республики Беларусь, за 2014 г. зарегистрировано 3835 новых случаев РМЖ. Из этого числа 82,2 % заболеваний было выявлено на ранних стадиях опухолевого процесса. Лечение по радикальной программе получили 75,2 % женщин. Пятилетняя выживаемость пациенток с впервые уста-новленным диагнозом РМЖ в 2009 г. составила 76 %, среди женщин с I и II стадиями заболевания -85,6 %, с III стадией -58,6 %, с IV стадией -14,1 %. Смерт-ность от злокачественных новообразований молочной железы составила в 2014 г. 21 на 100 тыс. женщин [1].Таким образом, лечение первичного РМЖ является сложной и не окончательно решенной на сегодняшний день проблемой. На современном этапе план лечебных мероприятий включает, как правило, несколько компо-нентов: хирургическое лечение, лучевое лечение, ХТ, гормонотерапию в случае положительных гормональ-ных рецепторов в опухоли и таргетную терапию при экспрессии опухолью эпидермального фактора ро-ста 2-го типа (НЕR-2 / neu).Однако факторы, приводящие к развитию отда-ленных метастазов, до сих пор недостаточно изучены.

show abstract

Immunocytochemical detection of epithelial cells in the bone marrow of primary breast cancer patients: a meta-analysis

Abstract: We conclude that the finding of epithelial cells in BM of BC patients correlates with several known prognostic factors and has adverse impact in the DFS and OS of these patients that seems, however, to decrease with time.

Cited by 19 publications

References 26 publications

Real-time RT–PCR detection of disseminated tumour cells in bone marrow has superior prognostic significance in comparison with circulating tumour cells in patients with breast cancer

Real-time RT–PCR detection of disseminated tumour cells in bone marrow has superior prognostic significance in comparison with circulating tumour cells in patients with breast cancer

Significance, detection and markers of disseminated breast cancer cells

Treatment of patients with bone marrow metastases: the present state of the problem

Contact Info

Product

Resources

About